Organon plans to continue research and development aiming at clinical application of the Academic Medical Center (AMC) for treatment of rheumatoid arthritis and possible other diseases. Under the
The researchers reported that rats receiving the diabetes drug Actos before, during and after radiation treatments did not experience cognitive impairment. The scientists compared whether treatment with Actos
The neuroscience partnership announced in April 2004 between Solvay and Wyeth has already resulted in a new drug application for bifeprunox for the treatment of patients with schizophrenia.
Elaprase replaces the enzyme, iduronate-2-sulfatase (I2S), that people with this disorder fail to produce in sufficient quantities. This lack of enzyme interferes with the body’s ability to break
The primary endpoint of the trial was statistical non-inferiority versus combination therapy. Ceftobiprole demonstrated high cure rates in patients with skin infections including diabetic patients with foot infections.
According to Roche the expansion of the product label provides benefits for the patients as they will no longer have the burden of three injections per week. Anemia
MedImmune is currently paying royalties under protest to Genentech for the use of an antibody technology for its drug Synagis, used in respiratory problems of children. MedImmune wishes
More than 1000 patients were recruited from around the world to participate in the study, which was conducted by Merck KGaA, ImClone Systems’ Erbitux partner outside of North
The proposed transaction remains subject to other customary closing conditions, including approval of the transaction by Conor Medsystems' stockholders. The companies hope to close the $1.4 billion transaction
C. Nicholas Hodge, Amphora's CSO and founder, said: “We are delighted that Genentech sees the potential value of one of our early stage programs. I personally see this
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.